, Volume 39, Issue 5, pp 674–680 | Cite as

Treatment Approaches to Reflux Oesophagitis

  • David Lieberman
Practical Therapeutic


The management of oesophageal reflux disease can and should be highly individualised, depending on the severity of the disease. Mild occasional symptoms of heartburn can often be controlled with conservative measures or changes in diet and antacids. For patients with erosive or ulcerative oesophageal disease, it is becoming clear that acid plays a crucial role in injury and that suppression of acid enhances healing. Antipeptic dosages of histamine receptor antagonists achieve good relief of symptoms but may not always heal erosive oesophagitis. Healing rates are improved with the use of new hydrogen-potassium adenosine triphosphatase (ATPase) pump inhibitors which suppress virtually all acid production. The recurrence of disease is common after acid suppression therapy is discontinued, suggesting the need for some form of long term maintenance therapy. Promotility drugs, which improve oesophageal motility, have inconsistent results in clinical trials and have been associated with a higher rate of adverse drug effects in comparison with acid-suppressive therapies. Surgical treatment should still be considered for patients with chronic recurrent disease who do not respond well to pharmacological therapies.


Metoclopramide Gastric Content Reflux Esophagitis Domperidone Adenosine Triphosphatase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Behar J, Sheahan DG, Biancini P, et al. Medical and surgical management of reflux esophagitis: a 38-month report on a prospective clinical trial. New England Journal of Medicine 293: 263–268, 1975PubMedCrossRefGoogle Scholar
  2. Biancani P, Barwick K, Selling J, McCallum R. Effects of acute experimental esophagitis on mechanical properties of the lower esophageal sphincter. Gastroenterology 87: 8–16, 1984PubMedGoogle Scholar
  3. Brand DL, Eastwood IR, Martin D, et al. Esophageal symptoms, manometry and histology before and after antireflux surgery: a long-term follow-up study. Gastroenterology 76: 1393–1401, 1979PubMedGoogle Scholar
  4. Colin-Jones DG. Histamine-2 receptor antagonists in gastro-oesophageal reflux. Gut 30: 1305–1308, 1989PubMedCrossRefGoogle Scholar
  5. Dent J, Dodds WJ, Sekiguchi T, Hogan WJ, Arndorfer RC. Interdigestive phasic contractions of the human lower esophageal sphincter. Gastroenterology 84: 453–460, 1983PubMedGoogle Scholar
  6. Dodds WJ, Dent J, Hogan WJ, Helm JF, Hauser R, et al. Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. New England Journal of Medicine 307: 1547–1552, 1982PubMedCrossRefGoogle Scholar
  7. Evander A, Little AG, Riddell RH, Walther B, Skinner DB. Composition of the refluxed material determines the degree of reflux esophagitis in the dog. Gastroenterology 93: 280–286, 1987PubMedGoogle Scholar
  8. Helm JF, Dodds WJ, Pelc LR, et al. Effect of esophageal emptying and saliva on clearance of acid from the esophagus. New England Journal of Medicine 310: 284–288, 1984PubMedCrossRefGoogle Scholar
  9. Hetzel DJ, Dent T, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastro-enterology 95: 903–912, 1988Google Scholar
  10. Hewson EG, Yeomans ND, Angus PW, et al. Effect of ‘weekend therapy’ with omeprazole on basal and stimulated acid secretion and fasting plasma gastrin in duodenal ulcer patients. Gut 29: 1715–1720, 1988PubMedCrossRefGoogle Scholar
  11. Lieberman DA. Medical therapy for chronic reflux esophagitis. Annals of Internal Medicine 147: 1717–1720, 1987CrossRefGoogle Scholar
  12. Lieberman DA, Keeffe EB. Treatment of severe reflux esophagitis with cimetidine and metoclopramide. Annals of Internal Medicine 104: 21–26, 1986PubMedGoogle Scholar
  13. Lloyd DA, Borda IT. Food-induced heartburn: effect of osmolality. Gastroenterology 80: 740–741, 1981PubMedGoogle Scholar
  14. Mittal RK, Lange RC, McCallum RW. Identification and mechanism of delayed esophageal acid clearance in subjects with hiatus hernia. Gastroenterology 92: 130–135, 1987PubMedGoogle Scholar
  15. Orlando RC, Turjman NA, Tobey NA, Schreiner VJ, Powell DW. Mucosal protection by sucralfate and its components in acid-exposed rabbit esophagus. Gastroenterology 93: 352–361, 1987PubMedGoogle Scholar
  16. Richter JE. A critical review of current medical therapy for gastroesophageal reflux disease. Journal of Clinical Gastroenterology 92: 459–465, 1987Google Scholar
  17. Tielemans Y, Hakanson R, Sundler F, Willems G. Proliferation of enterochromaffin-like cells in omeprazole-treated hypergas-trinemic rats. Gastroenterology 96: 723–729, 1989PubMedGoogle Scholar

Copyright information

© ADIS Press Limited 1990

Authors and Affiliations

  • David Lieberman
    • 1
  1. 1.Oregon Health Sciences UniversityPortlandUSA

Personalised recommendations